39661258|t|Exploring the Neuroprotective Effects of Rufinamide in a Streptozotocin-Induced Dementia Model.
39661258|a|Due to the complex pathophysiology of AD (Alzheimer's Disease), there are currently no effective clinical treatments available, except for acetylcholinesterase inhibitors. However, CREB (cyclic AMP-responsive element binding protein) has been identified as the critical factor for the transcription in memory formation. Understanding the effect of potential drugs on the CREB pathway could lead to the development of new therapeutic molecules. Rufinamide has shown promise in improving memory in animal models, and these effects may be associated with modulation of the CREB pathway, however, this has not been previously reported. Thus, the present study aimed to determine the involvement of the CREB pathway in the cognitive improvement effects of rufinamide in STZ (streptozotocin) induced mouse model of dementia. Administration of STZ [3 mg/kg, i.c.v. (intracerebroventricular) bilaterally] significantly impaired cognitive performance in step-down passive avoidance and Morris water maze tests in animals, reduced brain endogenous antioxidant levels (GSH, superoxide dismutase, and catalase), and increased marker of brain oxidative stress [TBARS (thiobarbituric acid reactive substances)] and inflammation [IL-1beta (Interleukin-1 beta), IL-6 (Interleukin-6), TNF-alpha (Tumor necrosis factor alpha) and NF-kappaB (Nuclear factor kappa B)], along with neurodegeneration. These effects were markedly reversed by rufinamide (50 and 100 mg/kg) when administered to STZ animals. However, the pre-treatment with the CREB inhibitor (666-15) in STZ and rufinamide-administered animals neutralized the beneficial influence of rufinamide. Our data suggest that rufinamide, acting via CREB signaling, reduced oxidative stress and inflammatory markers while elevating anti-oxidant levels. Our study has established that rufinamide may act through CREB signaling in an investigational AD model, which could be crucial for developing new treatments beneficial in progressive neurological disorders.
39661258	41	51	Rufinamide	Chemical	MESH:C079703
39661258	57	71	Streptozotocin	Chemical	MESH:D013311
39661258	80	88	Dementia	Disease	MESH:D003704
39661258	134	136	AD	Disease	MESH:D000544
39661258	138	157	Alzheimer's Disease	Disease	MESH:D000544
39661258	277	281	CREB	Gene	12912
39661258	283	328	cyclic AMP-responsive element binding protein	Gene	12912
39661258	467	471	CREB	Gene	12912
39661258	540	550	Rufinamide	Chemical	MESH:C079703
39661258	666	670	CREB	Gene	12912
39661258	794	798	CREB	Gene	12912
39661258	847	857	rufinamide	Chemical	MESH:C079703
39661258	861	864	STZ	Chemical	MESH:D013311
39661258	866	880	streptozotocin	Chemical	MESH:D013311
39661258	890	895	mouse	Species	10090
39661258	905	913	dementia	Disease	MESH:D003704
39661258	933	936	STZ	Chemical	MESH:D013311
39661258	1007	1025	impaired cognitive	Disease	MESH:D003072
39661258	1154	1157	GSH	Chemical	MESH:D005978
39661258	1185	1193	catalase	Gene	12359
39661258	1244	1249	TBARS	Chemical	MESH:D017392
39661258	1251	1290	thiobarbituric acid reactive substances	Chemical	MESH:D017392
39661258	1297	1309	inflammation	Disease	MESH:D007249
39661258	1311	1319	IL-1beta	Gene	16176
39661258	1321	1339	Interleukin-1 beta	Gene	16176
39661258	1342	1346	IL-6	Gene	16193
39661258	1348	1361	Interleukin-6	Gene	16193
39661258	1364	1373	TNF-alpha	Gene	21926
39661258	1375	1402	Tumor necrosis factor alpha	Gene	21926
39661258	1408	1417	NF-kappaB	Gene	18033
39661258	1456	1473	neurodegeneration	Disease	MESH:D019636
39661258	1515	1525	rufinamide	Chemical	MESH:C079703
39661258	1566	1569	STZ	Chemical	MESH:D013311
39661258	1615	1619	CREB	Gene	12912
39661258	1642	1645	STZ	Chemical	MESH:D013311
39661258	1650	1660	rufinamide	Chemical	MESH:C079703
39661258	1722	1732	rufinamide	Chemical	MESH:C079703
39661258	1756	1766	rufinamide	Chemical	MESH:C079703
39661258	1779	1783	CREB	Gene	12912
39661258	1824	1836	inflammatory	Disease	MESH:D007249
39661258	1913	1923	rufinamide	Chemical	MESH:C079703
39661258	1940	1944	CREB	Gene	12912
39661258	1977	1979	AD	Disease	MESH:D000544
39661258	2066	2088	neurological disorders	Disease	MESH:D009461
39661258	Negative_Correlation	MESH:C079703	18033
39661258	Negative_Correlation	MESH:C079703	MESH:D003704
39661258	Association	MESH:C079703	12912
39661258	Association	MESH:D007249	18033
39661258	Negative_Correlation	MESH:C079703	MESH:D013311
39661258	Negative_Correlation	MESH:C079703	MESH:D017392
39661258	Positive_Correlation	MESH:D013311	21926
39661258	Positive_Correlation	MESH:D013311	18033
39661258	Positive_Correlation	MESH:D013311	16193
39661258	Negative_Correlation	MESH:C079703	MESH:D009461
39661258	Negative_Correlation	MESH:D013311	12359
39661258	Negative_Correlation	MESH:C079703	16176
39661258	Negative_Correlation	MESH:C079703	MESH:D000544
39661258	Positive_Correlation	MESH:D013311	MESH:D003704
39661258	Positive_Correlation	MESH:D013311	16176
39661258	Negative_Correlation	MESH:C079703	16193
39661258	Positive_Correlation	MESH:D013311	MESH:D017392
39661258	Negative_Correlation	MESH:D005978	MESH:D013311
39661258	Positive_Correlation	MESH:D013311	MESH:D003072
39661258	Negative_Correlation	MESH:C079703	MESH:D007249
39661258	Association	MESH:D007249	12912
39661258	Negative_Correlation	MESH:C079703	MESH:D019636
39661258	Negative_Correlation	MESH:C079703	21926
39661258	Association	MESH:D000544	12912
39661258	Positive_Correlation	MESH:D013311	MESH:D007249
39661258	Positive_Correlation	MESH:D013311	MESH:D019636

